Honest, paywall-free news is rare. Please support our boldly independent journalism with a donation of any size.
Image Credit: Gilead Sciences
As the number of confirmed COVID-19 cases worldwide approaches 4 million and the pandemic could be with us for months or years, we look at who can access drugs like remdesivir, being developed by pharmaceutical giant Gilead, which has the patent for the drug and is poised to make massive profits. We look at how much drugs like remdesivir will cost, and who can access them, with writer Achal Prabhala, coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa.
Please check back later for full transcript.
An important fundraising appeal: 10 Days to raise $50,000
Thank you for reading Truthout today. We have a brief message before you go.
Unfortunately, donations are down for Truthout at a time when media faces immense pressure. Yet, grassroots media is vital in the fight against Trump’s authoritarian reign. Our mandate to tell the truth, share strategies for resistance, and speak against fascism grows more urgent each day. We must appeal for your support.
If you can support Truthout with a one-time or monthly donation, you will make a significant impact on our work. Please donate during our fundraiser.